Everyone is Googling the future of work. With fingers crossed that their current “intelligent” role—knowledge worker, analyst, developer, scientist, consultant—won’t be the next…
Drug prescribing is entering a new chapter. For decades, clinicians have relied on broad guidelines, trial-and-error approaches, and limited genetic information to determine…
OneOme, a leading name in pharmacogenomics testing and personalized medicine, has announced that it will cease operations by November 14, 2025, citing ongoing…
For years, pharmacogenomics (PGx) was seen as a future promise, a fascinating science that could someday make drug therapy safer and more effective….
What if your next prescription could just as easily harm you, simply because of your genes? That unsettling question sits at the heart…
When you talk to Dr. Gualberto Ruaño, you don’t just hear about science — you hear about purpose. A physician, geneticist, and entrepreneur,…
Grand View Research has just released its latest report on the pharmacogenomics technology market, offering fresh insights into one of the fastest-growing areas…
Pharmacogenetic testing has emerged as one of the most exciting frontiers in personalized medicine. By analyzing a patient’s genetic makeup, these tests promise…
UGenome AI is a US based biotech software company developing next-generation tools for genomic data interpretation. Co-founded by CEO Zachary S. Brooks, Chief Strategy Office Peter Bannister, and Chief Genomics Officer Dr. Jayden Lee, PharmD, EMBA, the company specializes in secondary and tertiary genomic analysis—transforming raw sequencing data into actionable, repeatable insights.
The vendors profiled below deliver a mix of services, from laboratory testing to clinical decision support and pharmacist consultation. Each profile explains what the company does, why employers or TPAs might choose them, and what to verify during due diligence. You’ll also find typical use cases to guide selection and help you align the right PGx solution with your population health priorities.
End of content
End of content
Join Our Insider’s Circle! Stay up to Date with the latest in PGx